Loading...
•
Sep 30
LivaNova Q3 2025 Earnings Report
LivaNova reported strong third-quarter 2025 results, with double-digit reported and organic revenue growth, expanded operating margins, and raised full-year 2025 guidance.
Key Takeaways
LivaNova delivered a robust third quarter in 2025, achieving double-digit revenue growth across both reported and organic bases, driven by strong performance in its Cardiopulmonary and Neuromodulation segments. The company also demonstrated significant operating margin expansion and cash generation, leading to an upward revision of its full-year 2025 revenue, adjusted EPS, and adjusted free cash flow guidance.
Third-quarter revenue reached $357.8 million, marking a 12.5% increase on a reported basis compared to the prior year.
GAAP diluted earnings per share for the quarter was $0.49, while adjusted diluted earnings per share stood at $1.11.
Operating income for the third quarter was $54.0 million, with adjusted operating income at $80.4 million, reflecting strong operational performance.
LivaNova raised its full-year 2025 guidance for revenue growth, adjusted diluted earnings per share, and adjusted free cash flow, indicating confidence in continued strong performance.
LivaNova
LivaNova
LivaNova Revenue by Segment
LivaNova Revenue by Geographic Location
Revenue by Segment
Cardiopulmonary Revenue
CapyFin.comNeuromodulation Revenue
CapyFin.comOther Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comEurope Revenue
CapyFin.comRest of World Revenue
CapyFin.com Forward Guidance
LivaNova has raised its full-year 2025 guidance for revenue growth, adjusted diluted earnings per share, and adjusted free cash flow, reflecting strong performance and positive outlook.
Positive Outlook
- Full-year 2025 revenue growth range raised by 50 basis points to 8.5% to 9.5% on a constant-currency basis.
- Full-year 2025 organic revenue growth range raised to 9.5% to 10.5%.
- Full-year 2025 adjusted diluted earnings per share range raised by $0.10 at midpoint to $3.80 to $3.90.
- Full-year 2025 adjusted free cash flow range raised by $20 million at midpoint to $160 million to $180 million.
- Foreign currency expected to be a tailwind of approximately 1.0% for full-year 2025.
Challenges Ahead
- The company is unable to predict with reasonable certainty the type and extent of certain items that would impact GAAP measures but not non-GAAP measures.
- Reconciliation of forward-looking non-GAAP financial measures to GAAP measures is impractical due to uncertainty and variability.
- Assumes a share count of approximately 55 million for full-year 2025, which could fluctuate.
- Forward-looking statements are subject to known and unknown risks that are difficult to predict.
- Actual financial results, performance, achievements, or prospects may differ materially from forward-looking statements.
Revenue & Expenses
Visualization of income flow from segment revenue to net income